Laura J. Esserman, MD, from UCSF Helen Diller Family Comprehensive Cancer Center, discusses the I-SPY 2 trial, a clinical trial for women with newly diagnosed, locally advanced breast cancer.
Clinical Pearls
Laura J. Esserman, MD, professor, Departments of Surgery and Radiology, affiliate faculty, Institute for Health Policy Studies, University of California, San Francisco, director, Carol Franc Buck Breast Care Center; co-leader, Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the I-SPY 2 trial, a clinical trial for women with newly diagnosed, locally advanced breast cancer.
Pharmaceutical companies, diagnostic companies, academic institutions, and professionals worked together to evaluate drugs by class
Veliparib in combination with carboplatin showed benefit in triple-negative breast cancer
Researchers believe a phase III trial of veliparib plus carboplatin will be successful
